

# MOLECULAR DIVERSITY OF THE DOPAMINE RECEPTORS

*Olivier Civelli, James R. Bunzow, and David K. Grandy*

Vollum Institute for Advanced Biomedical Research, Oregon Health Sciences  
University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97201

KEY WORDS: Parkinson's disease, schizophrenia, D<sub>1</sub> D<sub>2</sub> D<sub>3</sub>, D<sub>4</sub> D<sub>5</sub>, G protein-coupled receptors

---

## INTRODUCTION

### *The Dopaminergic System and Its Relationship to Human Diseases*

Our current understanding of the relationship between the dopaminergic system and human brain disorders is based on two fundamental discoveries: dopamine-replacement therapy can alleviate Parkinson's disease (1-3) and, secondly, many antipsychotic drugs are dopamine receptor antagonists (4-7). These discoveries have guided two major directions in dopamine-related basic research and drug design: to activate dopamine receptors left understimulated by the degeneration of the afferent dopamine-secreting cells and to prevent dopamine from binding to its receptor, according to the hypothesis that schizophrenia is the result of dopamine receptor overactivity (5, 8). Since blockade of the dopamine receptors (antipsychotic therapy) can lead to a state similar to that resulting from dopamine depletion (Parkinson's therapy) and higher doses of dopamine can cause psychoses, the therapies of disorders resulting from dopamine imbalances are associated with adverse side effects. The ideal drug(s) that will treat one disorder without affecting the other has thus far not been found. However, the search for such a drug has led to the design of several dopamine receptor ligands that, in turn, have increased our understanding of the dopaminergic system. In particular, these studies have

led to the proposition that the etiology of movement disorders and psychoses involve different neuronal pathways and that the dopamine receptors may differ in these pathways. Here we review the latest developments regarding the dopamine receptors.

The dopaminergic system comprises three principal neuronal pathways: the nigrostriatal, the mesocorticolimbic, and the tuberoinfundibular. The nigrostriatal pathway contains the neurones of the substantia nigra, which synthesize dopamine and neurones of the striatum that respond to it. Degeneration of this pathway leads to Parkinson's disease, underscoring its role in the control of locomotion. The mesocorticolimbic pathway, composed of neurones of the ventral tegmental area that connect with those of the limbic forebrain, is thought to be involved in emotional stability, contributing to the etiology of schizophrenia, and to be the desired site of action of the neuroleptics. The tuberoinfundibular pathway originates in the neurones of the hypothalamus. The dopamine secreted by these neurones into the portal blood is transported to the pituitary to regulate prolactin secretion from the pituitary. This pathway influences lactation and fertility.

The dopaminergic system relies on the interaction of dopamine with several receptors. In 1979 two were known and characterized as the D<sub>1</sub> and D<sub>2</sub> receptors (9). These receptors can be differentiated pharmacologically using D<sub>1</sub> and D<sub>2</sub> receptor-selective agonists and antagonists. Of therapeutic interest, most of the commonly prescribed neuroleptics bind the D<sub>2</sub> receptor with high affinity. These two receptors exert their biological actions by coupling to and activating different G protein complexes. The D<sub>1</sub> receptor interacts with G<sub>s</sub> complexes resulting in the activation of adenylyl cyclase and in an increase in intracellular cAMP levels. The D<sub>2</sub> receptor interacts with G<sub>i</sub> complexes to inhibit cAMP production. These biological activities placed the two dopamine receptors in the superfamily of G protein-coupled receptors, a feature of utmost importance for their molecular characterization. The anatomical distributions of these two receptors overlap in the CNS, yet their quantitative ratios differ significantly in particular anatomical areas. It is noteworthy with respect to mental disorders, that both D<sub>1</sub> and D<sub>2</sub> receptors are present in the nigrostriatal and mesocorticolimbic pathways.

For ten years, the two-subtype classification could accommodate most of the activities attributed to the dopaminergic system. This has changed with the definitive demonstration of the existence of several other dopamine receptors. These receptors have been reviewed recently (10–12). How the existence of new dopamine receptors will modify our previous conceptions of the dopaminergic system cannot be totally foreseen at this time. This review discusses the first ramifications that the dopamine receptor heterogeneity has brought on our understanding of the dopaminergic system.

## HETEROGENEITY OF THE DOPAMINE RECEPTORS

### *Molecular Characterization of the Dopamine Receptors*

The molecular characterization of the dopamine receptors originated with the recognition that G protein-coupled receptors are evolutionarily related (13–15). The discovery of their heterogeneity results from the application of this concept.

The existence of a G protein-coupled receptor supergene family was proposed on the basis of two receptor sequences, the rhodopsin and  $\beta_2$ -adrenergic receptors. The rhodopsin receptor transmits light signals to the brain through its interaction with a specific G protein, known as transducin. The  $\beta$ -adrenergic receptors transmit adrenergic stimulation in heart and lung tissues by interacting with another G protein, known as  $G_s$ . When the molecular structure of the  $\beta_2$ -adrenergic receptor was determined (16), its putative topology was found to be similar to that of the rhodopsin receptor. Both receptors were proposed to contain seven (putative) transmembrane domains in which several conserved amino acid residues are found. These similarities led to the concept that all receptors that couple to G protein to induce second messenger pathways might share these common structural characteristics. This concept was rapidly strengthened by the cloning of the acetylcholine-muscarinic<sub>2</sub> and of the neuropeptide-substance K receptors (17–20).

An important outcome of the concept that G protein-coupled receptors share sequence similarities was the development of technical approaches applicable to the cloning of any G protein-coupled receptors without previous knowledge of the receptor's peptide sequence or of its biological activity (21). These approaches, referred to as "homology approaches," rely on the use of DNA probes encoding sequences expected to be conserved among G protein-coupled receptors and can be technically divided into: (a) The low-stringency screening approach, which uses DNA fragments (>300bp) as hybridization probes to identify homologous sequences under hybridization conditions of reduced stringency, and (b) the PCR (polymerase chain reaction)-based homology approach, which uses oligonucleotides, complementary to short (<50b) highly conserved sequences, as primers to amplify related cDNAs in polymerase chain reactions. The first approach led to the characterization of the  $D_2$ , the second was used for the  $D_1$  dopamine receptors.

The  $D_2$  dopamine receptor was cloned using the hamster  $\beta_2$ -adrenergic receptor coding sequence as hybridization probe (22). A rat brain cDNA was identified via genomic and cDNA screenings and shown to encode a protein featuring the characteristics expected for a G protein-coupled receptor. This cDNA was transfected into eukaryotic cells and led to the expression of a receptor with the pharmacological profile and biological activity of the

dopamine D<sub>2</sub> receptor found in the brain and pituitary (22–24). In particular, the cloned receptor presented the expected affinity for neuroleptics and its stimulation inhibited adenylyl cyclase activity and prolactin secretion. This receptor is encoded by a gene (DRD<sub>2</sub>) located on human chromosome 11q23 (25).

The PCR-based approach was used to clone the D<sub>1</sub> receptor from rat striatum (26, 27) and mouse NS20Y neuroblastoma cells (28), although the low-stringency screening approach was also successful (29). The resulting partial clones were used to screen human and rat DNA libraries. The sequences derived from these clones share the characteristics expected of G protein-coupled receptors in general and of the catecholamine receptors in particular (26). These putative receptors were expressed by DNA transfection and were shown to bind D<sub>1</sub> receptor ligands and to stimulate adenylyl cyclase activity, the two hallmarks of the D<sub>1</sub> receptor. The human D<sub>1</sub> receptor gene (DRD<sub>1</sub>) is located on chromosome 5q35.1 (27, 30).

The success of the homology approach led to the search for other dopamine receptors. The D<sub>3</sub> receptor was originally identified by using a DNA fragment of the D<sub>2</sub> receptor as probe under low stringency hybridization conditions (31). Subsequent PCR extension and genomic library screening led to the isolation of a cDNA that encodes a receptor most closely related to the D<sub>2</sub> receptor. When expressed in eukaryotic cells, this receptor was shown to bind D<sub>2</sub> but not D<sub>1</sub> ligands. Although its ability to affect second messenger systems has not been demonstrated, its structure and binding characteristics permitted its classification as the D<sub>3</sub> receptor and has been assigned to chromosome 3q13.3 in human (DRD<sub>3</sub>) (32).

By analyzing the mRNAs of human neuroepithelioma SK-N-MC cells with D<sub>2</sub> receptor cDNA probes under conditions of low stringency, another D<sub>2</sub>-related mRNA was detected (33). The corresponding cDNA and gene analyses led to the characterization of the D<sub>4</sub> receptor. The D<sub>4</sub> receptor, when expressed in COS-7 cells, binds D<sub>2</sub> antagonists with a pharmacological profile distinct from, but reminiscent of, that of the D<sub>2</sub> receptor. Although the D<sub>4</sub> receptor can couple to G proteins, it has not been conclusively shown to modulate adenylyl cyclase activity. Its gene (DRD<sub>4</sub>) is located at the tip of the short arm of the human chromosome 11p15 (34).

Finally, the D<sub>1</sub> receptor clone was used as a hybridization probe to identify D<sub>1</sub>-related genes. A human D<sub>5</sub> and a rat D<sub>1b</sub> receptors were subsequently characterized (35–37). They display the same pharmacological profile, reminiscent of that of the D<sub>1</sub> receptor and are able to stimulate adenylyl cyclase activity. On the basis of their sequences, the D<sub>5</sub> and D<sub>1b</sub> receptors are human and rat equivalents of the same receptor, respectively. The human D<sub>5</sub> receptor maps to 4p15.1-p15.3 (38).

Three “unexpected” dopamine receptors, D<sub>3</sub>, D<sub>4</sub> and D<sub>5</sub>, were discovered

through the application of homology screening techniques. The existence of dopamine receptors different from the canonical D<sub>1</sub> and D<sub>2</sub> receptor had been proposed over the past decade but had been refuted when receptors were recognized to exist in two affinity states (39, 40). One definitive outcome of the cloning of receptors is to make them physical entities. The cloned D<sub>3</sub>, D<sub>4</sub> and D<sub>5</sub> receptors had not been previously characterized in detail.

## COMMON FEATURES OF THE DIFFERENT DOPAMINE RECEPTORS


The action of dopamine was, for the past decade or more, interpreted through its interactions with only two receptors. The discovery of the D<sub>3</sub>, D<sub>4</sub>, and D<sub>5</sub> receptors immediately raised the question whether the activities of these new receptors had been masked by those of the classical D<sub>1</sub> and D<sub>2</sub> receptors. The search for features common to both the new receptors and the classical ones can help resolve that possibility. The data presented here allows us to divide the dopamine receptors into two subfamilies, the D<sub>1</sub>-like (D<sub>1</sub>, D<sub>5</sub>) and the D<sub>2</sub>-like (D<sub>2</sub>, D<sub>3</sub>, D<sub>4</sub>) subfamilies (Table 1).

### *Gene Organization*

The genomic organization of the dopamine receptors supports the notion that they derive from the divergence of two gene families, which can be divided into the D<sub>1</sub>-like and D<sub>2</sub>-like receptor genes (Figure 1). The D<sub>1</sub>-like receptor genes do not contain introns in their protein-coding regions, whereas the D<sub>2</sub>-like genes do (26, 27, 31, 33, 41). Such a gene organization differentiating two receptor subfamilies (D<sub>1</sub>-like and D<sub>2</sub>-like) has also been described for other G protein-coupled receptor gene families, including the serotonin (5HT<sub>1a</sub>-like and 5HT<sub>1c</sub>-like) receptors (42). Strengthening this notion, several introns in the D<sub>2</sub>-like receptor genes are located in similar positions (Figure 1). It is noteworthy that two introns (after transmembrane domain IV and at the 3' half of the third cytoplasmic loop) were found in the D<sub>2</sub> and D<sub>3</sub> receptor genes to correspond almost precisely to intron positions found in the opsin genes (41). These introns are, however, absent in the D<sub>4</sub> receptor gene. Finally, two features of interest have been described regarding the genomic organization of the D<sub>2</sub> receptor gene: it contains an unusually long intron (250 kb) dividing its mRNA 5'-untranslated region; 150 kb downstream of the D<sub>2</sub> gene is the N-CAM gene (J. H. Eubanks, M. Djabali, L. Selleri, D. K. Grandy, O. Civelli, et al, submitted).

### *Sequence and Topology*

The overall topology of the five dopamine receptors is predicted to be highly similar. They should contain seven putative membrane-spanning  $\alpha$  helices,



**Figure 1** Genomic organization of the human dopamine receptor genes (data from refs. 31, 33, 36, 41, 74). Lines indicate introns, boxes exons; striped boxes with Roman numerals show the location of the putative transmembrane domains, shaded boxes those of the untranslated region of the corresponding mRNA; the pointed exon in the D<sub>2</sub> receptor gene is the alternatively spliced exon differentiating D<sub>2</sub>s from D<sub>2</sub>s (41). The seven repeats found in some human genes are outlined in hatched boxes in the D<sub>4</sub> receptor gene (91).

hallmark of the G protein-coupled receptors (44). By homology to the rhodopsin and adrenergic receptors, each of the dopamine receptor polypeptides should have its amino and carboxy termini located outside and inside the cell, respectively. The seven transmembrane domains would form a narrow dihedral hydrophobic cleft surrounded by three extracellular and three intracellular loops. The receptor polypeptides are probably further anchored to the membranes through palmitoylation of a conserved Cys residue found in their C-tails (347 in D<sub>1</sub>, the C-terminus in D<sub>2</sub>-like receptors) (45).

The dopamine receptors contain consensus sequences for glycosylation sites in the N-terminal domain, in addition the D<sub>1</sub>-like subtypes have potential glycosylation sites in their first extracytoplasmic loop. D<sub>1</sub> and D<sub>2</sub> receptors are known to be naturally glycosylated (46) and the cloned D<sub>2</sub> receptor also has been shown to be glycosylated when expressed in an heterologous cell (47). It is noteworthy that these experiments have also shown that the D<sub>2</sub> receptor exhibits a different glycosylation pattern when isolated from different cells and that, since the differently glycosylated receptors have the same pharmacological profile, the glycosylated moiety does not affect ligand recognition.

### *Ligand Binding*

Analogous to the mode of ligand recognition by the rhodopsin and adrenergic receptors, the binding of dopaminergic ligands must involve each receptor's hydrophobic core. This view is supported by the fact that the highest degree of sequence identity is found in the hydrophobic domains. Within their transmembrane domains, the amino acid sequences of the dopamine receptors are 31% identical (Figure 2). This percent increases to 75% and 52% if they are divided into D<sub>1</sub>-like and D<sub>2</sub>-like receptors, respectively.

The mechanism by which dopamine binding to the receptor induces G protein activity is unknown but most likely involves a cascade of intramolecular reactions. In particular, charged and conserved amino acid residues found in transmembrane domains should participate in dopamine recognition. Indeed, molecular models confirm that the charged residues of the  $\alpha$  helices face the inside part of the hydrophobic cleft (48). An Asp (103 in D<sub>1</sub>, and 114 in D<sub>2</sub>) in transmembrane III and two Ser (199–202 in D<sub>1</sub> and in D<sub>2</sub>) in transmembrane domain V could interact with the amine and the hydroxyl groups of dopamine, respectively (48–50). This model was recently tested experimentally and proven valid although the two serine residues in transmembrane domain V differentially affect agonist binding (51). In addition, the dopamine-receptor interaction might be stabilized by the interactions of two Phe residues (Phe 203–289 in D<sub>2</sub>, in transmembrane V and VI) with the benzene ring and by three aromatic residues (Trp 284, Phe 288, Phe 617) which could form an aromatic cluster around the aspartate ammonium ion pair (48). Furthermore, in transmembrane domains II and VII, Asp 70(D<sub>1</sub>) or 80(D<sub>2</sub>) and Asn 324(D<sub>1</sub>) or 390(D<sub>2</sub>) might be involved in agonist binding (52, 53). Indeed, mutations of the Asp 80 in the D<sub>2</sub> receptor lead to receptors with different ligand affinities and impaired in their potency to inhibit adenylyl cyclase (54). Finally, two Cys residues found in extracytoplasmic loops (96–186 in D<sub>1</sub> and 107–182 in D<sub>2</sub>) might form a disulfide bond that could affect ligand binding (49).

The cloned dopamine receptors, when expressed by transfection, exhibit binding profiles differentiating them into the D<sub>1</sub>-like and D<sub>2</sub>-like subfamilies. The D<sub>1</sub>-like receptors bind with high affinity D<sub>1</sub> and not D<sub>2</sub> antagonists. A prototypic ligand for the D<sub>1</sub>-like receptors is the benzazepine SCH23390 ( $K_{is} < 1\text{ nM}$ ). On the other hand they bind the butyrophenone spiperone with low affinity ( $K_{is}$  in the  $\mu\text{M}$  range). In contrast, the D<sub>2</sub>-like receptors bind efficiently spiperone ( $K_{is} < 1\text{ nM}$ ) and not SCH23390 ( $K_i$  for D<sub>2</sub> in the  $\mu\text{M}$  range); they also recognize most of the neuroleptics. While there is presently no ligand that differentiates the D<sub>1</sub> from the D<sub>5</sub> receptor, several D<sub>2</sub> antagonists can distinguish the different D<sub>2</sub>-like receptors (see below). At the structural level, 21 amino acid residues differentiate D<sub>1</sub>-like from D<sub>2</sub>-like receptors in the transmembrane domains, and these might participate in the selective recognition process (Figure 2).

### *G Protein Coupling and Desensitization*

The receptors' interactions with G proteins involve the cytoplasmic loops (55, 56). The D<sub>2</sub>-like receptors have a large third cytoplasmic loop and a short C-terminal tail, whereas the D<sub>1</sub>-like receptors have a relatively short third cytoplasmic loop and a long C-tail. Since both receptor domains have been implicated in G-protein coupling, their relative homology suggests that

**VII**

D1 ....DSNTFDVFVWEGWANSLSNPILIIYA.FNADERKAFSTLL..GQYRLCPATNNAIETVSINNNGAMFSSHHE

D2 .....VLYSATFNLGYVNSAVNPILIIYTTENIERKAFKIL..HC

D3 .....ELYSATFNLGYVNSALNPVIYTTENIERKAFKIL..SC

D4 .....RLVSATFNLGYVNSALNPVIYTVFNAEDERNVFKILACC

D5 EPCVSETTFDVFVWEGWANSLSNPILIIYA.FNADCKVFAQLL..CGSHFCSRTPVETVNISNELISYNQDIVFHK



receptors of the same subfamily might couple to the same set of G proteins. While this is true for the D<sub>1</sub>-like receptors whose stimulation leads to an increase in cAMP levels, it remains to be shown for all the D<sub>2</sub>-like receptors.

In their cytoplasmic domains, each of the dopamine receptors contains several consensus sites for phosphorylation by cAMP-dependent protein kinase or protein kinase C (22, 26). Several of these sites are present in the third cytoplasmic loop. Biochemical studies have shown that phosphorylation of such residues may attenuate G protein-receptor interactions and that these residues are directly involved in the homologous and heterologous mechanisms of desensitization (57). Since D<sub>2</sub> receptors are subject to desensitization when transfected into heterologous cells (47) while D<sub>1</sub> receptor desensitization occurs in striatal slices (58), model systems can now be established to test whether dopamine receptor phosphorylation affects desensitization.

The data discussed in this section show that the dopamine receptors can be divided into two subfamilies, the D<sub>1</sub>-like and D<sub>2</sub>-like subfamilies. That the D<sub>1</sub> and D<sub>2</sub> receptors are quantitatively predominant, particularly in the central nervous system (see below), may explain why most of the activities attributed to dopamine could be accounted for by the simpler two-receptors system (9). On the other hand, the novel D<sub>3</sub>, D<sub>4</sub>, and D<sub>5</sub> dopamine receptors each have their *raison d'être*, which might be found by searching for their specific features.

## SELECTIVITIES ASSOCIATED WITH THE DIFFERENT DOPAMINE RECEPTORS

The studies made possible by the use of dopamine receptor clones have allowed the discoveries of distinctive features of the different receptor subtypes. This section presents some of these results, in particular those that have helped us reevaluate our understanding of the dopaminergic system and of its roles in brain disorders (Table 1).

### *Selectivities in Pharmacological Profiles*

Thus far, no selective ligand able to differentiate the D<sub>1</sub> from the D<sub>5</sub> receptor has been described. The salient feature of the D<sub>5</sub> receptor is that it binds dopamine with a higher affinity than does the D<sub>1</sub> receptor (35, 36). On the other hand, the pharmacological profiles of the D<sub>3</sub> or D<sub>4</sub> receptors are reminiscent of, yet distinct from, that of the D<sub>2</sub> receptor. Most neuroleptics were developed as D<sub>2</sub> receptor antagonists and have a higher affinity for the D<sub>2</sub> than the D<sub>3</sub> or D<sub>4</sub> receptors. This implies that most of the neuroleptics are still acting predominantly at D<sub>2</sub> receptors in the human brain. However, the few exceptions that have been described are striking. One may help differen-

**Table 1** Particularities of the different dopamine receptor subtypes.

	D <sub>1</sub> -LIKE		D <sub>2</sub> -LIKE		
	D <sub>1</sub>	D <sub>5</sub>	D <sub>2</sub>	D <sub>4</sub>	D <sub>3</sub>
GENE and mRNA Chromosome	5q	4p	11q	3q	11p
Selective gene expression		Human pseudogenes 2p, 1q	Alternative splicing D2S/D2L		Polymorphism in human
Intron in coding seq.		NO		YES	
PROTEIN Seq. identity in TM (%)		100		45	
PHARMACOLOGY					
Prototypic antagonist		SCH23390		SPERONE	
Selective antagonist			Haloperidol	AJ76, UH232	Clozapine
BIOLOGY					
Guanylnucl. sensitivity	yes	yes	yes	no	yes
Adenylyl cyclase	activation	activation	inhibition	?	(?)
Other pathways	IP3 <sup>†</sup> , Ca channel		IP3 <sup>†</sup> , K channel		
LOCALIZATION					
Respectively high	caudate-putamen nucl. accumbens olfact. tubercle	hippocampus hypothalamus	caudate-putamen nucl. accumbens olfact. tubercle substantia nigra zona incerta pituitary, adrenal	olfact. tubercle hypothalamus nucl. accumbens islands of Calleja	frontal cortex medulla midbrain mesolimbic system heart
Selective	amygdala	parafascicular nucl. kidney			

tiate pre- from postsynaptic receptors, and the other could impact our understanding of the action of an atypical neuroleptic.

### *The Dopamine Presynaptic Receptors*

The receptors harboring a D<sub>2</sub>-like pharmacology have been subdivided into pre- and postsynaptic receptors (59). The postsynaptic receptors convey dopamine messages in the postsynaptic cells by inducing a second messenger system, e.g. by decreasing intracellular cAMP levels. The presynaptic or autoreceptors are present on the cells that secrete dopamine. Their stimulation by dopamine is thought to lead to an inhibition of impulse flow, co-transmitter release, and dopamine synthesis and release, thereby regulating dopamine production via a feed-back mechanism. Whether differences exist between pre- and postsynaptic receptors is controversial.

The D<sub>3</sub> receptor binds two antagonists with a higher affinity than does the D<sub>2</sub> receptor (31). These compounds, UH232 and AJ76, are classified as selective for the presynaptic receptors and are the only ligands known to date to be more selective for the D<sub>3</sub> than the D<sub>2</sub> receptor. In addition, dopamine was found to bind the D<sub>3</sub> receptor with a 20-fold higher affinity than the D<sub>2</sub> receptor, a characteristic expected for autoreceptors. Furthermore, the presence of D<sub>3</sub> receptor mRNA in the substantia nigra, a center of dopamine production, supports the hypothesis that the D<sub>3</sub> receptor may be a presynaptic receptor. Note also that the D<sub>2</sub> receptor mRNA is the predominant dopamine receptor mRNA in the substantia nigra (60) and that, like the D<sub>3</sub> receptor,

6-OHDA lesions show D<sub>2</sub> presence in the dopamine-secreting neurons (31, 61–64). Therefore, both the D<sub>2</sub> and the D<sub>3</sub> receptors are autoreceptors. Whether they are present in the same cells and whether stimulation of the D<sub>3</sub> receptor affects the presynaptic neuron differentially than does the D<sub>2</sub> receptor remain to be determined.

### *The D<sub>4</sub> Receptor Connection to Schizophrenia*

Except for clozapine, the D<sub>4</sub> receptor has a lower affinity for neuroleptics than does the D<sub>2</sub> receptor. Clozapine is an “atypical” neuroleptic, i.e. a neuroleptic in which actions are not accompanied by adverse motor control side effects. In schizophrenia therapy, clozapine is administered at a concentration tenfold lower than its affinity constant for the D<sub>2</sub> receptor, indicating that clozapine may not be primarily acting at the D<sub>2</sub> receptor. Since the D<sub>4</sub> receptor binds clozapine with a tenfold higher affinity than does the D<sub>2</sub> receptor (33), it could be classified as the specific clozapine target. A corollary is that antagonism of dopamine binding to the D<sub>4</sub> receptor could be an important step in the prevention of psychoses. Compared to the D<sub>2</sub> gene, the D<sub>4</sub> gene is expressed at low levels, suggesting that D<sub>4</sub> receptor-mediated activities are difficult to detect and thus were lost in measurements of D<sub>2</sub> receptor reactivity. Moreover, preliminary data on the tissue distribution of the D<sub>4</sub> mRNA shows that it is most abundant in the frontal cortex, midbrain, amygdala, and medulla, areas associated with psychotic etiologies, and at very low level in the striatum, the site of motor control (S. Watson, personal communication). Thus, the lack of extrapyramidal side effects observed with clozapine treatment may be a reflection of D<sub>4</sub> receptor localization in the CNS. These observations point to the D<sub>4</sub> receptor as an important molecule in balancing emotional control and may serve as a basis for understanding atypical neuroleptic actions.

### *Selectivities in Biological Activities*


The predominant biological activities associated with D<sub>1</sub> and D<sub>2</sub> receptor stimulation are the activation and inhibition, respectively, of adenylyl cyclase activity. The D<sub>2</sub> receptor in lactotroph cells also induces opening of K<sup>+</sup> channels and affects phosphoinositide hydrolysis upon dopamine binding (65). The establishment of cell lines expressing individual dopamine receptors through DNA transfection has permitted definitive analyses of each receptor's potential to induce second messenger systems.

### *Second Messenger Pathways Induced by the D<sub>1</sub> and D<sub>2</sub> Receptors*

The ability of dopamine receptors to induce different second messenger pathways has thus far been studied in D<sub>1</sub> and D<sub>2</sub> receptors (66, 67). The D<sub>1</sub> and D<sub>2</sub> receptors induce two types of signal transduction pathways, one

obligatory and several cell-specific. The obligatory pathway is detected in every cellular environment. In D<sub>1</sub> or D<sub>2</sub> receptors it is stimulation or inhibition of adenylyl cyclase, respectively. But dopamine also induced additional and sometimes different signal transduction pathways in Ltk-fibroblast, GH4C1 somatomammotroph, 293 kidney, CHO ovarian, and C6 glioma cells through its interaction with the D<sub>1</sub> and D<sub>2</sub> receptors.

In every cell studied, dopamine stimulation of the D<sub>1</sub> receptor increases cAMP production. In addition, in GH4C1 cells, the D<sub>1</sub> receptor potentiates



**Figure 3** Signaling pathways of the D<sub>1</sub> and D<sub>2</sub> dopamine receptors in the mouse fibroblast Ltk- and the rat somatomammotroph GH4C1 cells. Data are taken from (66, 67). DA represents dopamine, CTX and PTX means cholera toxin- and pertussis toxin-sensitive, respectively. G = G protein; PLC = Phospholipase C; AC = Adenylyl cyclase; PIP<sub>2</sub> = Phosphoinositol bisphosphate; IP<sub>3</sub> = Inositol triphosphate. The direction of arrows indicates whether the second messenger increases or decreases.

activation of L-type voltage-dependent calcium channel in a cAMP-dependent manner (Y. F. Liu, O. Civelli, Q. Y. Zhou, P. R. Albert, submitted). In Ltk-cells, D<sub>1</sub> receptor stimulation leads to an increase in cytosolic free calcium concentrations ( $[Ca^{++}]_i$ ) by mobilization of the intracellular calcium. This effect correlates with an increase in phospholipase C activity (PLC) and is cholera-toxin sensitive (67). The D<sub>2</sub> receptor, while inhibiting adenylyl cyclase activity, does not affect phosphoinositide (PI) hydrolysis in GH4C1 cells and induces a decrease in  $[Ca^{++}]_i$  mediated by a hyperpolarizing effect, mostly due to activation of K<sup>+</sup> channels. In Ltk-cells, the D<sub>2</sub> receptor stimulation leads to an increase in  $[Ca^{++}]_i$  due, in part, to the release of calcium ions from intracellular stores following the rapid stimulation of PI hydrolysis and, in part, to influx from extracellular medium. This surprising induction in PI hydrolysis is not due to the presence of nonphysiological concentrations of D<sub>2</sub> receptors in the cells. PI hydrolysis is induced by dopamine in Ltk-cells containing low levels of D<sub>2</sub> receptor (G. Gatti, C. Muca, E. Chiaregatti, D. K. Grandy, O. Civelli, et al, submitted). In addition, in CHO cells, D<sub>2</sub> receptors mediate the potentiation of arachidonic acid release by a mechanism that involves protein kinase C and that is independent of the concurrent adenylyl cyclase inhibition (69).

These data show that dopamine receptors can potentially induce different second messenger pathways in different cellular environments. The obligatory signaling pathway is always induced while the others are cell-dependent. This dual ability has been described for other G protein-coupled receptors (70–72) and points to the importance of the cellular environment in the outcome of receptor stimulation.

### *The Lack of Coupling of the D<sub>3</sub> Receptor to G Protein*

The search for the second messenger pathways induced by D<sub>3</sub> receptor stimulation has led to the surprising conclusion that the D<sub>3</sub> receptor does not seem to link to G proteins (31). The binding of dopamine to the D<sub>3</sub> receptor expressed into CHO or COS-7 cells is not modulated by the addition of guanylnucleotides, which differentiate the high- from the low-affinity state of G protein-coupled receptor and is accepted as an indication of effective G protein to receptor coupling. In addition, the D<sub>3</sub> receptor was unable to affect adenylyl cyclase activity. One possibility is that the D<sub>3</sub> receptor associates selectively with G proteins absent in the test cells. Since, in general, G protein-coupled receptors find G proteins to couple to in CHO and COS-7 cells, the possibility that the D<sub>3</sub> receptor does not couple to G protein might be entertained. In view of its possible autoreceptor nature (see above), it could, for example, act as a scavenger to modulate dopamine release from the presynaptic membrane but would not directly affect intracellular chemistry. However, since the binding of somatostatin to one of its specific receptor

has also been recently found to be insensitive to the addition of guanylnucleotides (73), it is our understanding of guanylnucleotides action that may need to be revised.

### *Regulation of D<sub>1</sub> and D<sub>2</sub> Receptor Gene Expression*

Therapies directed at disorders involving the dopamine receptors are administered over long periods of time. In animals these drug treatments modify the levels of dopamine receptor. It has been suggested that these changes may account for some of the side effects of the drugs. The availability of dopamine receptor clones allowed pilot studies to define which step in the expression of the receptor is affected by these drug-induced changes. Furthermore, genomic elements are also beginning to be characterized that recognize the transcriptional factors modulating dopamine receptor expression.

### *Regulation of Expression of the D<sub>1</sub> Receptor Gene In Vitro*

The D<sub>1</sub> promoter sequences of the rat and human D<sub>1</sub> receptor genes have been determined (74, 75). The D<sub>1</sub> gene contains a small intron that interrupts the 5' untranslated region of its mRNA. The region upstream of the start of transcription does not contain the canonical CAAT or TATA sequences, is G+C rich, and contains multiple potential sites for transcription factors.

Genomic sequences located upstream of the start of transcription (cap site) were evaluated for their ability to direct transcription of the receptor mRNA. It was found that the 735 bases upstream of the cap site were sufficient to confer transcriptional activity and that this activity was cell-specific. Cells endogenously expressing D<sub>1</sub> receptor could express D<sub>1</sub> receptor using this DNA fragment as the promoter, whereas others could not. In addition, it was observed that the D<sub>1</sub> gene promoter is induced in response to cAMP (75), suggesting the existence of an autoregulatory mechanism in D<sub>1</sub> gene expression. Activation of the D<sub>1</sub> receptor by dopamine increases intracellular cAMP level which leads, among other results, to receptor desensitization and enhancement of D<sub>1</sub> gene transcription. Since the D<sub>1</sub> receptor undergoes a very fast turnover (76), the increase in de novo protein synthesis is used as a compensatory mechanism to maintain a sustained dopamine activation. Such a mechanism has been proposed for the  $\beta_2$ -adrenergic receptor and might be shared by stimulatory receptors (77, 78).

### *Modulation of D<sub>2</sub> mRNA levels in vivo*

The importance of the D<sub>2</sub> receptor in schizophrenia and Parkinson's disease led to two lines of experiments analyzing changes in D<sub>2</sub> receptor mRNA levels.

Chronic neuroleptic administration, the traditional antipsychotic treatment, increases striatal dopamine D<sub>2</sub> receptor binding sites in rats (79). This increase

can account for the behavioral supersensitivity of the drug treatment. Whether the mechanism of this increase involves transcription has been analyzed by measuring D<sub>2</sub> mRNA levels by Northern blot analysis, solution, and in situ hybridization in rats subjected to long-term haloperidol administration. Several reports have concluded that the D<sub>2</sub> mRNA density in the basal ganglia is not affected by this treatment and have suggested that the increases in binding sites may be the result of increased protein stability (80, 81). However, the opposite has also been reported. Chronic haloperidol treatment increases striatal D<sub>2</sub> mRNA levels significantly, doubling it in some cases (82). These conflicting findings need to be reevaluated with regard to the method of mRNA detection and the drug regimen. It is noteworthy that chronic haloperidol treatment differentially affects D<sub>2</sub> mRNA levels in the pituitary, increasing them in the intermediate but not in the anterior lobe (83).

Denervation and degeneration by 6-hydroxydopamine of dopamine neurons have been used as a model for parkinsonism in rats. While the levels of striatal D<sub>2</sub> mRNA increase by about 30% after denervation (84), conflicting results were found after 6-OHDA treatment. Two studies found that the 6-OHDA treatment increases striatal D<sub>2</sub> mRNA by in situ hybridization (63, 64), while one found no change by Northern blot analyses (85). Here again, the methods of detection and the drug paradigms need to be carefully considered. The definitive answer to these questions may be obtained only after these paradigms have been reproduced in cell lines.

### *Selectivity in Tissue Distribution*

One advantage to the organism of an heterogeneous population of dopamine receptors is that it permits selective tissue-specific expression. This would imply that distinct receptor subtypes are expressed in different tissues. Since antibodies against all the different dopamine receptors are not currently available, our knowledge of their tissue distribution comes primarily from in situ hybridization experiments. In the central nervous system, the five dopamine receptors each overlap but also exhibit some striking location differences. In the periphery, the different receptors are mostly expressed in a tissue-specific fashion.

### *CNS Distribution*

The D<sub>1</sub> and D<sub>2</sub> receptor mRNAs are present in all dopaminoceptive regions of the rat brain (60, 61, 86–90). High levels of D<sub>1</sub> and D<sub>2</sub> mRNAs are present in the caudate-putamen, nucleus accumbens and olfactory tubercle, lower levels in the septum, hypothalamus and cortex. Regions where D<sub>2</sub> but no D<sub>1</sub> mRNAs were detected are the substantia nigra and ventral tegmental area, where the D<sub>2</sub> mRNA is expressed at high level, and the hippocampus. Conversely, the amygdala contains D<sub>1</sub> mRNA but little if any D<sub>2</sub> mRNA.

The tissue distribution of the D<sub>1</sub> and D<sub>2</sub> mRNAs in the CNS supports their participation in the different aspects of dopaminergic neurotransmission that have been described on the basis of ligand binding and receptor autoradiography experiments.

Since the tissue distribution of the different dopamine receptors overlap in the CNS, some selectivity may be attained quantitatively rather than qualitatively. First, (as judged from mRNA band intensities (31)) D<sub>3</sub>, D<sub>4</sub>, and D<sub>5</sub> mRNAs are one to two orders of magnitude lower in abundance than D<sub>1</sub> or D<sub>2</sub> mRNAs (31, 33, 37). Moreover, the relative abundance of the D<sub>1</sub> mRNA is striatum > amygdala > thalamus > mesencephalon > hypothalamus = medulla, that of the D<sub>2</sub> is striatum > mesencephalon > medulla > hypothalamus > hippocampus (22, 26). By comparison, the relative abundance of the D<sub>3</sub> receptor mRNA is olfactory tubercle-Islands of Calleja > nucleus accumbens = hypothalamus > striatum > substantia nigra, it is absent in the hippocampus (31), while that of the D<sub>4</sub> mRNA is medulla = amygdala > midbrain = frontal cortex > striatum > olfactory tubercle > hippocampus (33). So, relative to the D<sub>1</sub> or D<sub>2</sub> receptors, the D<sub>3</sub> and D<sub>4</sub> receptors are more selectively associated with the "limbic" brain, a region that receives its dopamine input from the ventral tegmental area and is associated with cognitive, emotional, and endocrine functions. The location of the D<sub>5</sub> receptor mRNA, on the other hand, is a matter of controversy. The distribution of the D<sub>5</sub> receptor mRNA was first reported to overlap that of the D<sub>1</sub> mRNA (35), but two studies have subsequently conflicted with this view (37, 91). These authors found that the tissue distribution of the D<sub>5</sub> mRNA tissue is highly restricted. The D<sub>5</sub> mRNA is found only in the hippocampus, the hypothalamus, and the parafascicular nucleus of the thalamus and thus might be involved in affective, neuroendocrine, or pain-related aspects of dopaminergic function (91). That the D<sub>5</sub> receptor mRNA is present at a very low level and thus can be easily masked by the predominant D<sub>1</sub> receptor mRNA probably explains the discrepancies in tissue distribution.

One important question unresolved before in situ hybridization experiments was that of the cellular colocalization of the D<sub>1</sub> and D<sub>2</sub> receptors (60). In brain regions where both mRNAs exist, the amounts of each are approximately equal. Analysis of sequential thin sections reveals that D<sub>1</sub> and D<sub>2</sub> mRNA are colocalized in 26–40% of all caudate-putamen cells and in about 50% of all dopamine receptor mRNA-positive cells.

### *Peripheral Distribution*

The D<sub>1</sub> and D<sub>3</sub> receptor mRNAs are practically absent outside of the CNS (26, 31), although the presence of D<sub>1</sub> mRNA in the parathyroid gland, a prototypic location of the D<sub>1</sub> binding site, has not been analyzed thus far. The D<sub>2</sub> receptor mRNA is expressed at high level in the pituitary (22) where



its physiological role in regulating hormone secretion is well-known. No D<sub>1</sub>, D<sub>3</sub> or D<sub>5</sub> receptor mRNA was detected in the pituitary where the D<sub>4</sub> mRNA exists, albeit at low level (92). Finally, the D<sub>2</sub> mRNA is also present in the adrenal gland (H. H. M. Van Tol, J. R. Bunzow, O. Civelli, unpublished data).

A major question about the peripheral dopamine receptors concerns the identity of the receptors present in the kidney and the cardiovascular system; do they differ from those of the CNS as indicated by pharmacological analyses (94)? The peripheral dopamine receptors are of therapeutic importance since their stimulation is used to improve kidney function in case of shock and low cardiac output. Both D<sub>1</sub>- and D<sub>2</sub>-like activities have been described in the kidney and in the heart (40, 94). The D<sub>5</sub> receptor mRNA is expressed, albeit at low level, in the kidney (J. H. Meador-Woodruff, D. K. Grandy, unpublished data). Whether it is the expected D<sub>1</sub>-like receptor or yet another one has not been demonstrated. None of the cloned D<sub>2</sub>-like receptor mRNAs is present in the kidney. On the other hand, the D<sub>4</sub> mRNA is expressed in the heart (96) and might account for the expected D<sub>2</sub>-like reactivity reported for this tissue. The D<sub>1</sub>-like receptor mRNAs do not exist in any significant amount in the heart. These data open the possibility that the D<sub>4</sub> and D<sub>5</sub> receptors are the only dopamine receptors present in the kidney and the heart, an hypothesis that must be investigated pharmacologically and physiologically.

In summary, the different dopamine receptors exhibit specificity in their tissue distribution in the periphery. In the CNS, they often share tissue locations and, possibly, individual neurones as in the case of the D<sub>1</sub> and D<sub>2</sub> receptors, although selectivity in cellular distributions has also been found. Furthermore, some selectivity in receptor reactivity may also be gained quantitatively, as suggested by the relative abundance of the subtypes. This abundance indicates that interactions between different subtypes, such as those described between the D<sub>1</sub> and D<sub>2</sub> receptors (97–100), may be an important factor in the regulation of dopamine actions.

### *Genomic Polymorphism and Alternative pre-mRNA Maturation*

Although the human genome as seen now contains five dopamine receptor genes, it encodes a higher number of mRNA species. This increase in complexity results from the discovery that polymorphism and alternative splicing events play a role in dopamine receptor gene expression and leads to the existence of more than five different receptor binding sites. Alternative splicing events and genomic polymorphism have been described for other genes and shown to be physiologically important in several cases (101–104).

## *Two Alternative Forms of the D<sub>2</sub> Receptor*

That different dopamine receptors can be expressed from a single gene was first demonstrated by the existence of not one but two dopamine D<sub>2</sub> receptor cDNAs (41, 105–111). These two forms differ in 29-amino acid residues located in the putative third cytoplasmic loop of the receptor. They are generated by an alternative splicing event that occurs during the maturation of the D<sub>2</sub> receptor pre-mRNA (41, 106, 111). This event was demonstrated by the discovery of an 87-bp exon encoding the additional amino acid residues. The 29-amino acid addition contains two potential glycosylation sites but thus far nothing is known about their physiological importance, if any (41). The two D<sub>2</sub> receptor forms are neither species- nor tissue-specific. They exist in human, rat, bovine, mouse, and frogs; they coexist in all tissues analyzed but at a highly variable ratio. The shorter form is the least abundant, its concentration is very low in the pituitary but it represents about half of the D<sub>2</sub> receptor mRNA in the pons or medulla (107, 111).

The presence of a 29-amino acid addition in the third cytoplasmic loop should a priori not affect ligand recognition. Although this was shown for D<sub>2</sub> receptor antagonists whose affinities for the two forms are the same (41, 107), it remains to be shown for agonists. Due to its location in the third cytoplasmic loop, however, the addition was expected to affect G-protein coupling and consequently second messenger systems. It has been shown that both forms can inhibit cAMP accumulation (106). Whether they do so with different efficiencies has been analyzed in two reports. In one report, CHO lines shown to express the same quantities of receptors were established. In these cells, the short form can maximally inhibit cAMP production by up to 85% while the long form can only reach 64% (112). In the other report, a human choriocarcinoma line, JEG-3, was established that expresses  $\beta_2$ -adrenergic receptors (113). Stimulation of this receptor was measured via the cascade of events that leads from the increase in adenylyl cyclase activity to the increase of CREB (cAMP-responsive element-binding protein) binding to CRE. This activation was monitored using a reporter gene containing the CRE sequence linked to CAT (chloramphenicol acetyltransferase) gene, whose activity can be measured biochemically. These cells were transiently transfected with either of the two D<sub>2</sub> receptor form cDNAs and inhibition of cAMP production was reflected by corresponding inhibition in CAT activity. In these assays, the short form of the D<sub>2</sub> receptor elicited a stronger effect on adenylyl cyclase inhibition than the long form (74% versus 61% at 10  $\mu$ M dopamine) and a lower affinity (EC<sub>50</sub> 58 nM versus 72 nM). Part of these latter findings might be accounted for by the discovery that the 87 bases differentiating the two receptor forms have a unusually high intrinsic CREB-binding property (M. Martin, J. R. Bunzow, unpublished data). In any case, the merging concept

from these studies is that the short form of the D<sub>2</sub> receptor requires less dopamine to be stimulated and, as a result, cells expressing a higher level of the short form will be activated first. Thereafter, the differences in ratio between the two forms might reflect some physiological differences.

Alternative splicing events have also been shown to occur during the maturation of the D<sub>3</sub> dopamine receptor pre-mRNA (115, 116). These resulting mRNAs would direct the translation of truncated receptor proteins. Indeed, upon transfection of the truncated cDNAs, no dopamine-binding activity was detectable (115). It is thus possible that, in vivo, the truncated mRNAs are products of abnormal posttranscriptional processing, possibly a minor event detectable by the advent of PCR.

### *Polymorphism in the Human D<sub>4</sub> Receptor Gene*

Analysis of different human D<sub>4</sub> receptor cDNA sequences demonstrated that the D<sub>4</sub> receptor can exist in at least three variants (Figure 1). These variants differ in the number of 48 base-pair repeats contained in their putative third cytoplasmic loop (92). cDNAs harboring 2, 4, and 7 repeats have been identified from the neuroepithelioma cell line SKN-MC, pituitary, or substantia nigra. These and two more variant alleles have been detected in the genomes of different individuals, showing that a genetic polymorphism is responsible for the generation of the D<sub>4</sub> receptor variants. These repeats are not present in the rat gene, making the polymorphism possibly specific to humans. When expressed by DNA transfection, the variants containing 2, 4, and 7 repeats bind clozapine with equal affinities in the presence of sodium chloride. In the absence of sodium ions, however, the variants containing 2 and 4 repeats had a six- to eightfold lower dissociation constants for clozapine, while the affinity of the variant containing seven repeats was practically unaffected (92). Although the effects that the sodium ions have on receptors are not understood, these data indicate that the variants can behave differently with respect to the mechanism of ligand recognition. The presence of the repeats in the third cytoplasmic loop also suggests differences in G-protein coupling. Furthermore, the discovery of this polymorphism in the human population may enhance understanding of affective disorders at the molecular level.

### *The D<sub>5</sub> Receptor Pseudogenes*

The D<sub>5</sub> receptor gene is particular among the G protein-coupled receptors in that it is associated with two pseudogenes in the human genome (36). The three D<sub>5</sub> related genes are found on different chromosomes (117). Only one gene (DRD<sub>5</sub>, Chromosome 4 q15.1-q15.3) codes for the active receptor, the two others contain an 8 base-pair insertion that leads to a frame-shift. Since it was demonstrated by expression that the insertion is not part of an intron,

the two other genes (DRD<sub>5</sub>P1, Chromosome 2 p11.1-p11.2, and DRD<sub>5</sub>P2 Chromosome 1 q21.1) are genuine pseudogenes. Two facts are intriguing about the D<sub>5</sub> pseudogenes: they are embedded in more than 5000 bases that are practically identical on the three chromosomes; and they appear to be specific to human. The rat D<sub>5</sub> gene, which has the same sequence as the D<sub>1b</sub> gene, has no pseudogene (117) and some monkeys have only one (118). Together, these data suggest that the evolution of the D<sub>5</sub> pseudogenes is a very recent event that may be restricted to the primates. The D<sub>5</sub> pseudogenes could serve as markers to elucidate the evolutionary process that led to dopamine receptor heterogeneity.

## DOPAMINE RECEPTOR AND GENETIC LINKAGE TO HUMAN DISORDERS

Finally, the dopamine receptor clones have also been used to test for possible linkage between the receptor and human neuropsychiatric disorders. Several disorders associated with the malfunctioning of the dopamine system have a genetic component. The identification of restriction length polymorphisms (RFLPs) in the human dopamine receptors genes (25, 30, 119) has permitted their use as probes for linkage analyses of members of these families. Thus far, most studies have involved the D<sub>2</sub> receptor and have used a Taq1 RFLP found downstream of the poly A adenylation site of the D<sub>2</sub> receptor (25). Schizophrenia, Tourette syndrome, and manic depression have been found not to be directly associated with the RFLP of the D<sub>2</sub> receptor gene locus (120–123). Furthermore, the D<sub>2</sub> receptor peptide sequences of 14 schizophrenics and 4 controls have been found to be identical (124). Several similar studies are being conducted on D<sub>3</sub> and D<sub>4</sub> receptor genes. In contrast, linkage between the D<sub>2</sub> receptor and severe alcoholism has been reported (125). However, this finding has been a matter of controversy (126) and will undoubtedly be the subject of many more studies.

## CONCLUSIONS AND PERSPECTIVES

The identification of “unexpected” dopamine receptor subtypes has had a tremendous impact on our understanding of the dopaminergic system. The diversity of the physiological activities attributed to dopamine can now be analyzed knowing that a greater number of dopamine receptors are involved. The availability of receptor clones, receptor antibodies, and expressed receptor proteins will permit in-depth studies of the circuitry of the dopaminergic system and of the mechanisms regulating it at the genomic and cytoplasmic level. It will also allow us to decipher the physical structure of the receptors and permit the design of highly specific ligands. Eventually, therapies for

disorders associated with malfunction of the dopaminergic system should benefit from the discovery of the receptor heterogeneity. The possibility that the D<sub>3</sub> and D<sub>4</sub> receptors are preferential targets of some neuroleptics (such as the atypical ones) stands as a first example. Our renewed understanding of the dopaminergic system will perhaps shed light on the molecular basis of human psychoses and Parkinson's disease.

Whether other dopamine receptor subtypes exist is still unclear. Heterogeneity is common among G protein-receptor families but the number of members in each family varies (20, 127, 128). This variability indicates that one neurotransmitter can interact with a variety of receptors, a fact that helps support, at a molecular level, the complexity of synaptic transmissions. Interestingly, it seems that each family is composed of two major subtypes distinguishable in the type of obligatory signaling pathways that they induce. There are indications that other receptors in the dopamine receptor family may exist, thus far not cloned (40). A D<sub>1</sub>-like and a D<sub>2</sub>-like receptor have been detected through expression of their corresponding mRNA or gene but have not been sequenced (129, 130). Since the identification of a new receptor necessitates determination of its sequence, these and other previously detected novel dopamine receptor-like activities remain putative until associated with a defined molecule.

#### ACKNOWLEDGMENTS

We thank Hubert Van Tol and to Qun-Yong Zhou for many discussions, our lab colleagues and outside collaborators for their contributions to the work discussed in this review, and, in particular, S. Watson, A. Mansour, J. Meador-Woodruff, Huda Akil, J. Gelernter, M. Caron, M. Litt, S. Sommer, J. Ebanks, G. Evans, Y. F. Liu, P. Albert, J. Meldolesi, and L. Vallar for their invaluable help. We also acknowledge J. Tasnady for preparing the manuscript and J. Shiigi for illustrations. The work from our laboratory was supported in part by grants from the National Institute of Health (DK37231, MH45614, MH48991)

#### Literature Cited

1. Ehringer, H., Hornykiewicz, O. 1960. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des Extrapyramidalen Systems. *Klin. Wochenschr.* 38:1236-39
2. Birkmayer, W., Hornykiewicz, O. 1962. Der L-Dioxyphenylalanin (=L-DOPA)-Effekt beim Parkinson-Syndrom des Menschen: Zur Pathogenese und Behandlung der Parkinson-Akinese. *Arch. Psychiat. Nervenkr.* 203:560-74
3. Hornykiewicz, O. 1966. Dopamine and brain function. *Pharmacol. Res.* 18: 925-64
4. Carlsson, A., Lindqvist, M. 1963. Effect of chlorpromazine and haloperidol on the formation of 3-methoxytyramine in mouse brain. *Acta Pharmacol.* 20: 140-44
5. Carlsson, A. 1988. The current status

- of the dopamine hypothesis of schizophrenia. *Neuropsychopharmacology* 1:179-86
6. Creese, I., Burt, D. R., Snyder, S. H. 1976. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. *Science* 192:481-83
  7. Seeman, P., Lee, T., Chan-Wong, M., Wong, K. 1976. Antipsychotic drug doses and neuroleptic/dopamine receptors. *Nature* 261:717-19
  8. Seeman, P. 1987. Dopamine receptors and the dopamine hypothesis of schizophrenia. *Synapse* 1:133-52
  9. Keabian, J. W., Calne, D. B. 1979. Multiple receptors for dopamine. *Nature* 277:93-96
  10. Civelli, ●., Bunzow, J. R., Grandy, D. K., Zhou, Q. Y., Van Tol, H. M. M. 1991. Molecular biology of the dopamine receptors. *Eur. J. Pharmacol.* 207:277-86
  11. Grandy, D. K., Civelli, O. 1992. G-protein-coupled receptors: The new dopamine receptor subtypes. *Curr. Opin. Neurobiol.* In press
  12. Sibley, D. R., Monsma, F. J. Jr. 1992. Molecular biology of dopamine receptors. *Trends Pharmacol. Sci.* 13:61-69
  13. Dohman, H. G., Caron, M. G., Lefkowitz, R. J. 1987. A family of receptors coupled to guanine nucleotide regulatory proteins. *Biochemistry* 26: 2657-64
  14. Hall, Z. A. 1987. Three of a kind: The  $\beta$ -adrenergic receptor, the muscarinic acetylcholine receptor, and rhodopsin. *Trends Neurolog. Sci.* 10: 99-100
  15. Probst, W. C., Snyder, L. A., Schuster, D. I., Brosius, J., Sealfon, S. C. 1992. Sequence alignment of the G protein-coupled receptor superfamily. *DNA Cell Biol.* 11:1-20
  16. Dixon, R. A. F., Koblika, B. K., Strader, D. J., Benovic, J. L., Dolhman, H. G., et al. 1986. Cloning of the gene and cDNA for mammalian  $\beta$ -adrenergic receptor and homology with rhodopsin. *Nature* 321:75-79
  17. Masu, Y., Nakayama, K., Tamaki, H., Harada, Y., Kuno, M., et al. 1987. cDNA cloning of bovine substance-k receptor through oocyte expression system. *Nature* 329:836-38
  18. Kubo, T., Maeda, A., Sugimoto, K., Akiba, I., Mikami, A., et al. 1986. Primary structure of porcine cardiac muscarinic acetylcholine receptor deduced from the cDNA sequence. *FEBS Lett.* 209:367-72
  19. Peralta, E. G., Winslow, J. W., Peterson, G. L., Smith, D. H., Ashkenazi, A., et al. 1987. Primary structure and biochemical properties of an M2 muscarinic receptor. *Science* 236:600-5
  20. Bonner, T. I., Buckley, N. J., Young, A. C., Brann, M. R. 1987. Identification of a family of muscarinic acetylcholine receptor genes. *Science* 237: 527-32
  21. Bunzow, J. R., Zhou, Q. Y., Civelli, O. 1992. Cloning of dopamine receptors: Homology approach. *Meth. Neurosci.* 9:441-53
  22. Bunzow, J. R., Van Tol, H. H. M., Grandy, D. K., Albert, P., Salon, J., et al. 1988. Cloning and expression of a rat D<sub>2</sub> dopamine receptor cDNA. *Nature* 336:783-87
  23. Albert, P. R., Neve, K. A., Bunzow, J. R., Civelli, O. 1990. Coupling of a cloned rat dopamine D<sub>2</sub> receptor to inhibition of adenylyl cyclase and prolactin secretion. *J. Biol. Chem.* 265: 2098-104
  24. Neve, K. A., Henningsten, R. A., Bunzow, J. R., Civelli, O. 1989. Functional characterization of a rat dopamine D<sub>2</sub> receptor cDNA expressed in mammalian cell lines. *Mol. Pharmacol.* 36:446-51
  25. Grandy, D. K., Litt, M., Allen, L., Bunzow, J. R., Marchionni, M., et al. 1989. The human dopamine D<sub>2</sub> receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. *Am. J. Hum. Genet.* 45:778-85
  26. Zhou, Q. Y., Grandy, D., Thambi, L., Kushner, J., Van Tol, H. H. M., et al. 1990. Cloning and expression of human and rat D<sub>1</sub> dopamine receptors. *Nature* 347:76-80
  27. Sunahara, R. K., Niznik, H. B., Weiner, D. M., Storman, T. M., Brann, M. R., et al. 1990. Human dopamine D<sub>1</sub> receptor encoded by an intronless gene on chromosome 5. *Nature* 347:80-83
  28. Monsma, F. J. Jr., Mahan, L. C., McVittie, L. D., Gerfen, C. R., Sibley, D. R. 1990. Molecular cloning and expression of a D<sub>1</sub> dopamine receptor linked to adenylyl cyclase activation. *Proc. Natl. Acad. Sci. USA* 87:6723-27
  29. Dearry, A., Gingrich, J. A., Falardeau, P., Freneau, R. T., Bates, M. D., et al. 1990. Molecular cloning and expression of the gene for a human D<sub>1</sub> dopamine receptor. *Nature* 347:72-76
  30. Grandy, D. K., Zhou, Q. Y., Allen, L., Litt, R., Magenis, R. E., et al. 1990. A human D<sub>1</sub> dopamine receptor gene is located on chromosome 5 at

- q35.1 and identifies an EcoRI RFLP. *Am. J. Hum. Genet.* 47:828-34
31. Sokoloff, P., Giros, B., Martres, M. P., Bouthenet, M. L., Schwartz, J. C. 1990. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. *Nature* 347:146-51
  32. Giros, B., Martres, M. P., Sokoloff, P., Schwartz, J. C. 1990. Clonage du gene du recepteur dopaminergique D3 humain et identification de son chromosome. *C. R. Acad. Sci.* 311:501-8
  33. Van Tol, H. H. M., Bunzow, J. R., Guan, H. C., Sunahara, R. K., Seeman, P., et al. 1991. Cloning of a human dopamine D4 receptor gene with high affinity for the antipsychotic clozapine. *Nature* 350:610-14
  34. Gelernter, J., Kennedy, J. L., Van Tol, H. H. M., Civelli, O., Kidd, K. K. 1992. The D4 dopamine receptor (DRD4) maps to distal 11p close to HRAS. *Genomics* 13:208-10
  35. Sunahara, R. K., Guan, H. C., O'Dowd, B. F., Seeman, P., Laurier, L. G., et al. 1991. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. *Nature* 350:614-19
  36. Grandy, D. K., Zhang, Y., Bouvier, C., Zhou, Q. Y., Johnson, R. A., et al. 1991. Multiple D5 dopamine receptor genes: A functional receptor and two pseudogenes. *Proc. Natl. Acad. Sci. USA* 88:9175-79
  37. Tiberi, M., Jarvie, K. R., Silvia, C., Falardeau, P., Gingrich, J. A., et al. 1991. Cloning, molecular characterization and chromosomal assignment of a gene encoding a second D1 dopamine receptor subtype: Differential expression pattern in rat brain compared with the D1 receptor. *Proc. Natl. Acad. Sci. USA* 88:7491-95
  38. Eubanks, J. H., Altherr, M., Wagner-McPherson, C., McPherson, J. D., Wasmuth, J. J., et al. 1992. Localization of the D5 dopamine receptor gene to human chromosome 4p15.1-p15.3, centromeric to the Huntington's disease locus. *Genomics* 12:510-16
  39. Leff, S. E., Creese, I. 1985. Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum: Evidence the [<sup>3</sup>H] dopamine can label a high affinity agonist-binding state of the D1 dopamine receptor. *Mol. Pharmacol.* 27:184-92
  40. Andersen, P. H., Gingrich, J. A., Bates, M. D., Dearth, A., Falardeau, P., et al. 1990. Dopamine receptor subtypes: beyond the D1/D2 classification. *Trends Pharmacol. Sci.* 11:231-36
  41. Grandy, D. K., Marchionni, M. A., Makam, H., Stofko, R. E., Alfano, M., et al. 1989. Cloning of the cDNA and gene for a human D2 dopamine receptor. *Proc. Natl. Acad. Sci. USA* 86:9762-66
  42. Julius, D. 1991. Molecular biology of serotonin receptors. *Annu. Rev. Neurosci.* 14:335-60
  43. Deleted in proof
  44. Dohlman, H. G., Thorner, J., Caron, M. C., Lefkowitz, R. J. 1991. Model systems for the study of seven-transmembrane-segment receptors. *Annu. Rev. Biochem.* 60:653-88
  45. O'Dowd, B. F., Hnatowich, M., Caron, M. G., Lefkowitz, R. J., Bouvier, M. 1989. Palmitoylation of the human  $\beta_2$ -adrenergic receptor. *J. Biol. Chem.* 264:7564-69
  46. Strange, P. G. 1990. Aspects of the structure of the D2 dopamine receptor. *Trends Neurolog. Sci.* 13:373-78
  47. Bates, M. D., Gingrich, J. A., Bunzow, J. R., Falardeau, P., Dearth, A., et al. 1990. Molecular characterization of dopamine receptors. *Am. J. Hyperten.* 3:295-305
  48. Hibert, M. R., Trumpp-Kallmeyer, S., Bruinvels, A., Hoflack, J. 1991. Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. *Mol. Pharmacol.* 40:8-15
  49. Dixon, R. A. F., Sigal, I. S., Vandelore, M. R., Register, R. B., Scattergood, W., et al. 1987. Structural features required for ligand binding to the  $\beta$ -adrenergic receptor. *EMBO J.* 6:3269
  50. Strader, C. O., Candelore, M. R., Hill, W. S., Sigal, I. S., Dixon, R. A. F. 1989. Identification of two serine residues involved in agonist activation of the  $\beta$ -adrenergic receptor. *J. Biol. Chem.* 264:13572-78
  51. Mansour, A., Meng, F., Meador-Woodruff, J. H., Taylor, L. P., Civelli, O., et al. 1992. Site-directed mutagenesis of the human D2 receptor. *J. Biol. Chem.* In press
  52. Strader, C. D., Sigal, I. S., Register, R. B., Candelore, M. R., Rands, E., et al. 1987. Identification of residues required for ligand binding to the  $\beta$ -adrenergic receptor. *Proc. Natl. Acad. Sci. USA* 84:4384-88
  53. Strader, C. D., Sigal, I. S., Candelore, M. R., Rands, E., Hill, W. S., et al. 1988. Conserved aspartic acid residues 79 and 113 of the  $\beta$ -adrenergic receptor

- have different roles in receptor function. *J. Biol. Chem.* 263:10267-71
54. Neve, K. A., Cox, B. A., Henningsen, R. A., Spanoyannis, A., Neve, R. L. 1991. Pivotal role for aspartate-80 in the regulation of dopamine D<sub>2</sub>receptor affinity for drugs and inhibition of adenyl cyclase. *Mol. Pharmacol.* 39:733-39
  55. Dixon, R. A. F., Sigal, I. S., Strader, C. D. 1988. Structure-function analysis of the  $\beta$ -adrenergic receptor. *Cold Spring Harbor Symp.* 53:487-98
  56. Lefkowitz, R. J., Kobilka, B. K., Benovic, J. L., Bouvier, M., Cotecchia, S., et al. 1988. Molecular biology of adrenergic receptors. *Cold Spring Harbor Symp.* 53:507-14
  57. O'Dowd, B. F., Lefkowitz, R. J., Caron, M. G. 1989. Structure of the adrenergic and related receptors. *Annu. Rev. Neurosci.* 12:67-83
  58. Memo, M., Lovenberg, W., Habauer, I. 1982. Agonists-induced subsensitivity of adenylate cyclase coupled with a dopamine receptor in slices from rat corpus striatum. *Proc. Natl. Acad. Sci. USA* 79:4456-60
  59. Wolf, M. E., Roth, R. H. 1987. Dopamine autoreceptors. In *Dopamine Receptors*, ed. I. Creese, C. M. Fraser, pp. 45-96. New York: Liss
  60. Meador-Woodruff, J. H., Mansour, A., Healy, D. J., Kuehn, R., Zhou, A. Q., et al. 1991. Comparison of the distributions of D<sub>1</sub> and D<sub>2</sub> dopamine receptor mRNAs in rat brain. *Neuropsychopharmacology* 5:231-42
  61. Mansour, A., Meador-Woodruff, J., Bunzow, J., Civelli, O., Akil, H., et al. 1990. Localization of dopamine D<sub>2</sub>receptor mRNA and D<sub>1</sub> and D<sub>2</sub> receptor binding in the rat brain and pituitary: an in situ hybridization-receptor autoradiographic analysis. *J. Neurosci.* 10:2587-600
  62. Chen, J. F., Qin, Z. H., Szele, F., Bai, G., Weiss, B. 1991. Neuronal localization and modulation of the D<sub>2</sub>dopamine receptor mRNA in brain of normal mice and mice lesioned with 6-hydroxydopamine. *Neuropharmacology* 30:927-41
  63. Gerfen, C. R., Engber, T. M., Mahan, L. C., Susel, Z., Chase, T. N., et al. 1990. D<sub>1</sub> and D<sub>2</sub> dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. *Science* 250:1429-30
  64. Mansour, A., Meador-Woodruff, J. H., Camp, D. M., Robinson, T. E., Bunzow, J., et al. 1989. The effects of nigrostriatal 6-hydroxydopamine lesions on dopamine D<sub>2</sub> receptor mRNA and opioid systems. In *The International Narcotics Research Conference (INRC)*, pp. 227-30. New York: Liss
  65. Vallar, L., Meldolesi, J. 1989. Mechanisms of signal transduction at the dopamine D<sub>2</sub> receptor. *Trends Pharmacol. Sci.* 10:74-77
  66. Vallar, L., Muca, C., Magni, M., Albert, P., Bunzow, J., et al. 1990. Differential coupling of dopaminergic D<sub>2</sub> receptors expressed in different cell types. *J. Biol. Chem.* 265:1032-1036
  67. Deleted in proof
  68. Deleted in proof
  69. Kanterman, R. Y., Mahan, L. C., Briley, E. M., Monsma, F. J. Jr., Sibley, D. R., et al. 1990. Transfected D<sub>2</sub> dopamine receptors mediate the potentiation of arachidonic acid release in chinese hamster ovary cells. *Mol. Pharmacol.* 39:364-69
  70. Ashkenazi, A., Winslow, J. W., Peralta, E. G., Peterson, G. L., Schimerlik, M. I. et al. 1987. An M<sub>2</sub> muscarinic receptor subtype coupled to both adenyl cyclase and phosphoinositide turnover. *Science* 238:672-75
  71. Ashkenazi, A., Peralta, E. G., Winslow, J. W., Ramachandran, J., Capon, D. J. 1989. Functional diversity of muscarinic receptor subtypes in cellular signal transduction and growth. *Trends Pharmacol. Sci.* 10:16-22 (Suppl.)
  72. Stein, R., Pinkas-Kramarski, R., Sikolovsky, M. 1988. Cloned M<sub>1</sub> muscarinic receptors mediate both adenylate cyclase inhibition and phosphoinositide turnover. *EMBO J.* 7:3031-35
  73. Rens-Domiano, S., Law, S., Yamada, Y., Seino, S., Belle, G. I., et al. 1992. Pharmacological properties of two cloned somatostatin receptors. *Mol. Pharmacol.* In press
  74. Minowa, M. T., Minowa, T., Monsma, F. J. Jr., Sibley, D. R., Mouradian, M. M. 1992. Characterization of the 5' flanking regions of the human D<sub>1A</sub> dopamine receptor gene. *Proc. Natl. Acad. Sci. USA* 89:3045-49
  75. Zhou, Q. Y., Li, C., Civelli, O. 1992. Characterization of gene organization and promoter region of the rat dopamine D<sub>1</sub> receptor gene. *J. Neurochem.* In press
  76. Fuxe, K., Agnati, L. F., Pich, E. M., Meller, E., Goldstein, M. 1987. Evidence for a fast receptor turnover of D<sub>1</sub> dopamine receptors in various forebrain regions of the rat. *Neurosci. Lett.* 81:183-87
  77. Collins, S., Altschmied, J., Herbsman,



- O., Caron, M. G., Mellon, P. L., et al. 1990. A cAMP response element in the  $\beta_2$ -adrenergic receptor gene confers transcriptional autoregulation by cAMP. *J. Biol. Chem.* 265:19330-35
78. Hershey, A. D., Dykema, P. E., Krause, J. E. 1991. Organization, structure, and expression of the gene encoding the rat substance P receptor. *J. Bio. Chem.* 266:4366-74
79. Norman, A. B., Battaglia, G., Creese, I. 1987. Differential recovery rates of rat D<sub>2</sub> dopamine receptors as a function of aging and chronic reserpine treatment following irreversible modification: A key to receptor regulatory mechanisms. *J. Neurosci.* 7:1484-91
80. Van Tol, H. H. M., Riva, M., Civelli, O., Creese, I. 1990. Lack of effect of chronic dopamine receptor blockade on D<sub>2</sub> dopamine receptor mRNA level. *Neurosci. Lett.* 111:303-8
81. Srivastava, L. K., Morency, M. A., Bajwa, S. B., Mishra, R. K. 1990. Effect of haloperidol on expression of dopamine D<sub>2</sub> receptor mRNAs in rat brain. *J. Mol. Neurosci.* 2:155-61
82. Le Moine, C., Normand, E., Guitteny, A. F., Fouque, B., Teoule, R., et al. 1990. Dopamine receptor gene express by enkephalin neurons in rat forebrain. *Proc. Natl. Acad. Sci. USA* 87:230-34
83. Autelitano, D. J., Snyder, L., Sealfon, S. C., Roberts, J. L. 1989. Dopamine D<sub>2</sub>-receptor messenger RNA is differentially regulated by dopaminergic agents in rat anterior and neurointermediate pituitary. *Mol. Cell. Endocrinol.* 67:101-5
84. Neve, K. A., Neve, R. L., Fidel, S., Janowsky, A., Higgins, G. A. 1991. Increased abundance of alternatively spliced forms of D<sub>2</sub> dopamine receptor mRNA after denervation. *Proc. Natl. Acad. Sci.* 88:2802-6
85. Martres, M. P., Sokoloff, P., Giros, B., Schwartz, J. C. 1992. Effects of dopaminergic transmission interruption on the D<sub>2</sub> receptor isoforms in various cerebral tissues. *J. Neurochem.* 58:673-79
86. Meador-Woodruff, J. H., Mansour, A., Bunzow, J. R., Van Tol, H. H. M., Watson, S., et al. 1989. Distribution of D<sub>2</sub> dopamine receptor mRNA in rat brain. *Proc. Natl. Acad. Sci. USA* 86:7625-28
87. Mengod, G., Martinez-Mir, M. I., Vilaro, M. T., Palacios, J. M. 1989. Localization of the mRNA for the dopamine D<sub>2</sub> receptor in the rat brain by in situ hybridization histochemistry. *Proc. Natl. Acad. Sci. USA* 86:8560-64
88. Najlerahim, A., Barton, A. J. L., Harrison, P. J., Heffernan, J., Pearson, R. C. A. 1989. Messenger RNA encoding the D<sub>2</sub> dopaminergic receptor detected by in situ hybridization histochemistry in rat brain. *FEBS Lett.* 255:335-39
89. Weiner, D. M., Brann, M. R. 1989. The distribution of a dopamine D<sub>2</sub> receptor mRNA in rat brain. *FEBS Lett.* 253:207-13
90. Fremeau, R. T. Jr., Duncan, G. E., Fornaretto, M. G., Dearry, A., Gingrich, J. A., et al. 1991. Localization of D<sub>1</sub> dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission. *Proc. Natl. Acad. Sci. USA* 88:3772-76
91. Meador-Woodruff, J. H., Mansour, A., Grandy, D. K., Civelli, O., Watson, S. J. 1992. Distribution of D<sub>5</sub> dopamine receptor mRNA in rat brain. *FEBS Lett.* In press
92. Van Tol, H. H. M., Wu, C. M., Guan, H. C., Ohara, K., Bunzow, J. R., et al. 1992. Multiple dopamine D<sub>4</sub> receptor variants in the human population. *Nature* 358:149-52
93. Deleted in proof
94. Felder, R. A., Felder, C. A., Eisner, F. M., Jose, P. A. 1989. The dopamine receptor in adult and maturing kidney. *Am. Physiol. J.* F315-27
95. Deleted in proof
96. O'Malley, K. L., Harmon, S., Tang, L., Todd, R. D. 1992. The rat dopamine D<sub>4</sub> receptor: Sequence, gene, structure, and demonstration of expression in the cardiovascular system. *New Biol.* 4:137-46
97. Waddington, J. L. 1989. Functional interactions between D<sub>1</sub> and D<sub>2</sub> dopamine receptor systems: Their role in the regulation of psychomotor behavior, putative mechanisms, and clinical relevance. *J. Psychopharmacol.* 3:54-63
98. Walters, J. R., Bergstrom, D. A., Carlson, J. H., Chase, T. N., Braun, A. R. 1987. D<sub>1</sub> dopamine receptor activation required for postsynaptic expression of D<sub>2</sub> agonist effects. *Science* 269:719-22
99. Seeman, P., Niznik, H. B., Guan, H.-C., Booth, G., Ulpian, C. 1989. Link between D<sub>1</sub> and D<sub>2</sub> dopamine receptors is reduced in schizophrenia and Huntington diseased brain. *Proc. Natl. Acad. Sci. USA* 86:10156-60
100. Bertorello, A. M., Hopfield, J. F., Aperia, A., Greengard, P. 1990. Inhibition by dopamine of (Na<sup>+</sup> + K<sup>+</sup>) ATPase activity in neostriatal neurons

- through D<sub>1</sub> and D<sub>2</sub> dopamine receptor synergism. *Nature* 347:386-88
101. Orkin, S. M., Kazazian, H. H., Aultorarakis, S. E., Goff, S. C., Boehm, C., et al. 1982. Linkage of beta-thalassaemia mutations and beta-globin gene polymorphisms with DNA polymorphisms in human beta-globin gene cluster. *Nature* 296:627-31
102. Treisman, R., Orkin, S. H., Maniatis, T. 1983. Specific transcription and RNA splicing defects in five cloned  $\beta$ -thalassaemia genes. *Nature* 302:591-96
103. Mahadevan, M., Tsilfidis, C., Sabourin, L., Shutter, G., Amemiya, C., et al. 1992. Myotonic dystrophy mutation: An unstable CTG repeat in the 3' untranslated region of the gene. *Science* 255:1253-55
104. Fu, Y. H., Pizzuti, A., Fenwick, R. G. Jr., King, J., Rajnarayan, S., et al. 1992. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. *Science* 255:1256-58
105. Selbie, L. A., Hayes, G., Shine, J. 1989. The major dopamine D<sub>2</sub> receptors: Molecular analysis of the human D<sub>2A</sub> subtype. *DNA* 8:683-89
106. Dal Toso, R., Sommer, B., Ewert, M., Herb, A., Pritchett, D. B., et al. 1989. The dopamine D<sub>2</sub> receptor: Two molecular forms generated by alternative splicing. *EMBO J.* 8:4025-34
107. Giros, B., Sokoloff, P., Martres, M. P., Rious, J. F. 1989. Emorine, L. J., et al. Alternative splicing directs the expression of two D<sub>2</sub> dopamine receptor isoforms. *Nature* 342:923-26
108. Monsma, F. J. Jr., McVittie, L. D., Gerfen, C. R., Mahan, L. C., Sibley, D. R. 1989. Multiple D<sub>2</sub> dopamine receptors produced by alternative RNA splicing. *Nature* 342:926-29
109. Chio, C. L., Hess, G. F., Graham, R. S., Hugg, R. M. 1990. A second molecular form of D<sub>2</sub> dopamine receptor in rat and bovine caudate nucleus. *Nature* 343:266-69
110. Miller, J. C., Wang, Y., Filer, D. 1990. Identification by sequence analysis of a second rat brain cDNA encoding the dopamine D<sub>2</sub> receptor. *Biochem. Biophys. Res. Commun.* 166: 109-12
111. O'Malley, K. L., Mack, K. J., Gandelman, K. Y., Todd, R. D. 1990. Organization and expression of the rat D<sub>2A</sub> receptor gene: Identification of alternative transcripts and a variant donor splice site. *Biochemistry* 29: 1367-71
112. Hayes, G., Biden, T. J., Selbie, L. A. 1992. Structural subtypes of the dopamine D<sub>2</sub> receptor are functionally distinct: Expression of the cloned D<sub>2A</sub> and D<sub>2B</sub> subtypes in a heterologous cell line. *Mol. Endocrinol.* 6:920-26
113. Montmayeur, J. P., Borrelli, E. 1991. Transcription mediated by a cAMP-responsive promoter element is reduced upon activation of dopamine D<sub>2</sub> receptors. *Proc. Natl. Acad. Sci. USA* 88: 3135-39
114. Deleted in proof
115. Giros, B., Martres, M. P., Pilon, C., Sokoloff, P., Schwartz, J. C. 1991. Shorter variants of the D<sub>3</sub> dopamine receptor produced through various patterns of alternative splicing. *Biochem. Biophys. Res. Commun.* 176:1584-92
116. Snyder, L. A., Roberts, J. L., Sealfon, S. C. 1991. Alternative transcripts of the rat and human dopamine D<sub>3</sub> receptor. *Biochem. Biophys. Res. Commun.* 180:1031-35
117. Grandy, D. K., Allen, L. J., Zhang, Y., Zhou, Q. Y., Magenis, R. E., et al. 1992. Chromosomal localization of the three human D<sub>5</sub> dopamine receptor genes. *Genomics*. Submitted
118. Nguyen, T. 1991. Human dopamine D<sub>5</sub> receptor pseudogenes. *Gene* 109: 211-18
119. Hauge, X. Y., Grandy, D. K., Eubanks, J. H., Evans, G. A., Civelli, O., et al. 1991. Detection and characterization of additional DNA polymorphisms in the dopamine D<sub>2</sub> receptor gene. *Genomics* 10:527-30
120. Byerly, W., Leppert, M., O'Connell, P., Mellon, C., Holick, J., et al. 1990. D<sub>2</sub> dopamine receptor gene is not linked to manic-depression in three families. *Psychol. Genet.* 1:55-62
121. Gelernter, J., Pakstis, A., Pauls, D., Kurlan, R., Ganther, S. T., et al. 1990. Gilles de la Tourette syndrome is not linked to D<sub>2</sub> dopamine receptors. *Arch. Gen. Psychol.* 47:1073-77
122. Devor, E. J., Grandy, D. K., Civelli, O., Litt, M., Burgess, A. K., et al. 1990. Genetic linkage is excluded for the D<sub>2</sub>-dopamine receptor LHD<sub>2</sub>G<sub>1</sub> and flanking loci on chromosome 11q22-q23 in Tourette syndrome. *Hum. Hered.* 40:105-8
123. Moises, H. W., Gelernter, T., Grandy, D. K., Giuffra, L. A., Kennedy, J. L., et al. 1991. Exclusion of the D<sub>2</sub> dopamine receptor gene as candidate gene for schizophrenia. *Ann. Gen. Psychol.* 48:643-47
124. Sarkar, G., Kapelner, S., Grandy, D.

- K., Marchionni, M., Civelli, O., et al. 1991. Direct sequencing of the dopamine D<sub>2</sub> receptor (DRD<sub>2</sub>) in schizophrenics reveals three polymorphisms but no structural change in the receptor. *Genomics* 11:8-14
125. Blum, K., Noble, P., Sheridan, P. J., Montgomer, A., Ritchie, T., et al. 1990. Allelic association of human dopamine D<sub>2</sub> receptor gene in alcoholism. *J. Am. Med. Assoc.* 263: 2055-60
  126. Bolos, A. M., Dean, M., Lucas-Derse, S., Ramsburg, M., Brown, G. L., et al. 1990. Population and pedigree studies reveal a lack of association between the dopamine D<sub>2</sub> receptor gene and alcoholism. *J. Am. Med. Assoc.* 264: 3156-60
  127. Schwinn, D. J., Lomasney, J. W., Lorenz, W., Szklut, P. J., Freneau, R. T., et al. 1990. Molecular cloning and expression of the cDNA for a novel  $\alpha_1$ -adrenergic receptor subtype. *J. Biol. Chem.* 265:8183-89
  128. Emorine, L. J., Marullo, S., Briand-Sutren, M. M., Patey, G., Tate, K., et al. 1989. Molecular characterization of the human  $\beta_3$ -adrenergic receptor. *Science* 245:1118-21
  129. Mahan, L. C., Burch, R. M., Monsma, F. J., Sibley, D. R. 1990. Expression of striatal D<sub>1</sub> dopamine receptors coupled to inositol phosphate production and Ca<sup>2+</sup> mobilization in *Xenopus* oocytes. *Proc. Natl. Acad. Sci. USA* 87:2196-200
  130. Todd, R. D., Khurana, T. S., Sajovic, P., Stone, K. R., O'Malley, K. L. 1989. Cloning of ligand-specific cell lines via gene transfer: Identification of a D<sub>2</sub> dopamine receptor subtype. *Proc. Natl. Acad. Sci. USA* 86:10134-38